Moreover, we further analyzed the correlation of c-Myc/PD-L1expression with clinical outcomes by dividing 63 pancreatic cancer patients into four c-Myc/PD-L1 expression groups (c-Myc-high and PD-L1-high, c-Myc-low and PD-L1-high, c-Myc-high and PD-L1-low, c-Myc-low and PD-L1-low). The gene discussed is MYC; the disease is pancreatic neoplasm.